Ribosomopathies are a family of inherited disorders caused by mutations in genes necessary for ribosomal function. Shwachman-Diamond Bodian Syndrome (SDS) is an autosomal recessive disease caused, in most patients, by mutations of the SBDS gene. SBDS is a protein required for the maturation of 60S ribosomes. SDS patients present exocrine pancreatic insufficiency, neutropenia, chronic infections, and skeletal abnormalities. Later in life, patients are prone to myelodisplastic syndrome and acute myeloid leukemia (AML). It is unknown why patients develop AML and which cellular alterations are directly due to the loss of the SBDS protein. occurs when SBDS protein drops below a threshold level, and propose a new interpretation of the disease.
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Introduction
Ribosomopathies are inherited diseases due to the haploinsufficiency of ribosomal proteins or ribosome processing factors [1, 2] . Patients affected by ribosomopathies present multiorgan phenotypes [2] . Some relatively common features are bone marrow and skeletal deficits, and cancer predisposition [3, 4] . At the cellular level, ribosomal haploinsufficiency may cause the induction of tumor suppressor p53 [2, 5] . Consequently, in some models the depletion of p53 reduces the deleterious effects of ribosomal haploinsufficiency [6] [7] [8] [9] leading to the hypothesis that abnormal p53 is the pathogenic culprit. However, this is not true for all cases [10, 11] .
Shwachman-Diamond Syndrome (SDS) is a recessive ribosomopathy affecting 1 in 76,000 births. SDS is a multisystem disorder presenting in the first year of life and characterized by the hallmark of exocrine pancreatic dysfunction. Another common symptom is the susceptibility to chronic infections accompanied by neutropenia [12, 13] . With variable penetrance, patients affected by SDS may have low stature, skeletal defects and cognitive impairment [14, 15] . Finally, high risk of acute myeloid leukemia (AML) is associated with older patients [16] . Loss-of-function mutations in the SBDS gene have been identified as the cause of the disease [17] .
Several studies addressed the function of SBDS protein in mammals and of its yeast homolog. A concise survey will be presented. SBDS has a role in the maturation of 60S ribosomal subunits. Deletion of the yeast homolog sdo1 is quasi-lethal, leading to pre-60S nuclear export defects. Importantly, point mutations of tif6, a gene necessary for 60S biogenesis [18] , revert the quasi-lethal phenotype [19] . These and other studies, have led to a general model in which SBDS is necessary for the maturation of 60S subunits, in order to remove eIF6 (mammalian Tif6) from mature 60S subunits [20] [21] [22] . Since eIF6 controls 60S availability [23] and full translational activation [24, 25] , manipulation of the binding of eIF6 to the 60S may be critical for restoring SBDS-mutant cells. A recent report suggested that SBDS contributes to the efficient translation of C/EBPα and C/EBP-β mRNAs, uORF-containing mRNAs that are, among others, indispensable regulators of granulocytic differentiation [26] . A general analysis of translated mRNAs depending from SBDS is still lacking. We do not know in detail whether other steps of 60S maturation beside eIF6 release are affected.
Several studies have attempted to pinpoint other functions of the SBDS protein, in the obvious effort to explain the multiorgan phenotype of patients. At the cellular level, several phenotypes associated to SBDS loss have been described. These phenotypes have been largely observed either in primary cells from patients, or upon shRNA experiments in cell lines. Increased apoptosis driven by FAS was seen in HeLa upon SBDS shRNA [27] , and increased ROS production [28] . Increased apoptosis was also seen in SBDS-depleted HEK293 cells upon DNA and chemically induced endoplasmic reticulum stress [29] , and in hemopoietic cells [30] . SBDS association with mitotic spindle has been proposed [31] and the lack of SBDS has been associated with genetic instability [32] . In general, reduced clonogenic potential is observed in hematopoietic precursors upon SBDS depletion [9, 33] . Reduced respiratory capability has been observed in mammalian and yeast cells lacking SBDS or its homolog, Sdo1p [34, 35] . Overall, it is unclear whether the cellular phenotypes ascribed to the loss of SBDS activity are direct or indirect, general or cell-specific, and have a relationship with protein synthesis.
Recently, a mouse strain in which one of the most frequent missense mutation found in SDS patients is modeled, R126T, has been produced [36] . This mouse model reproduces the clinical symptoms of SDS patients. We exploited the availability of this model to address the cell autonomous effects due to hypomorphic SBDS alleles. We have derived from these mice embryonic fibroblast cell lines, we have reconstituted control MEFs with wild type SBDS and then performed a full characterization of their properties. We addressed in SBDS mutant cells their predisposition to oncogenic transformation, changes in eIF6 binding, transcriptional and translational changes, metabolic parameters, and sensitivity to drugs and stresses. We unveiled several features due to the loss of SBDS. We provide a pathogenic model of SBDS deficiency that focuses on a diminished anabolic and energetic status of Sbds mutant cells due to reduced protein synthesis, which may be useful to design rational therapeutic ameliorative strategies.
Results

Sbds mutant cells are resistant to oncogene induced transformation
Swhachman-Diamond (SDS) patients have an higher incidence of blood tumors, mainly acute myeloid leukemia (AML) [37] . This observation raises the question whether SBDS mutant cells are intrinsically susceptible to oncogene-mediated transformation. SBDS point mutation R126T corresponds to a common mutation found in SDS patients (c.377G>C) and it has been modeled in mice [36] . We immortalized R126T mouse embryonic fibroblasts (MEFs), together with their matched wild type controls, and we evaluated their capability to form colonies. Two strategies can be employed for immortalization of MEFs, a) sequential subcloning [38] or b) immortalization and transformation with oncogenes and tumor suppressor inhibitors [39] . By sequential subcloning, we were unable to derive Sbds R126T/R126T MEFs due to early senescence ( Fig 1A) , whereas we normally derived wt cells. This result is in line with a recent work describing early senescence in the pancreas of SBDS mutants [8] . (Fig 1B and 1C) . We then plated wt MEFs and Sbds MEFs in soft agar, another indicator of transformation efficiency, to test their capability to grow in anchorage independent condition. We found that surviving clones of Sbds
R126T/R126T
MEFs grew as well as wt cells (Fig 1D) , but their overall number was lower than the one of wt MEFs (Fig 1E) . In order to evaluate the capability of these transformed colonies to induce tumor in vivo, we injected 500.000 transformed cells in nude mice and monitored tumor mass R126T/R126T and wild type MEFs (n = 7 per genotype): death time point is defined at 400mm 3 tumor volume, when mice were euthanized. Number of colonies expressed as mean ± s.d. Statistic applied for (B-E) was t-test, paired, two-tailed (*P value 0.05, ***P 0.001). Log-rank (Mantel-Cox) Test (***P 0.0001) was applied to (F). showed a complete rescue of the profile (Fig 2B) , confirming a direct action of SBDS on ribosome maturation, and validating our model for discriminating direct versus clonal or indirect effects. We analyzed rRNA precursors with a pulse-chase assay by monitoring the incorporation of 5,6 3 H-uridine in the nascent ribosomal RNA (S2A Fig). We did not observe differences in rRNA maturation associated with the SBDS mutation, a result consistent with the idea that only the late maturation of 60S is affected by SBDS deficiency. The nucleolus is the nuclear compartment where both ribosome biogenesis and early maturation occur. A defect in ribosomal export can be assessed by measuring the number and the size of nucleoli. We did not observe differences in the number of nucleoli between Sbds R126T/R126T and wild type cells (Fig 2C) or in Sbds MOCK and Sbds RESCUE cells (Fig 2D) . In addition, we did not observe differences in co-localization of SBDS and nucleolar marker nucleophosmin (NPM) between Sbds R126T/R126T and wild type cells (Fig 2E and 2F ). eIF6 nucleolar localization was relatively similar in Sbds R126T/R126T and wild type cells (S2B Fig). eIF6 binds 60S subunits, blocking 80S formation and increasing free 60S peak [24] . It has been proposed that SBDS deficiency blocks eIF6 release [20] . This model is consistent with the accumulation of free 60S that we observed (Fig 2A) . We recently developed a Ribosomes Interaction Assay (Fig 2G) , able to quantify eIF6 binding sites on the 60S [40] . We immobilized equal ribosomes from Sbds R126T/R126T and wild type cells, and measured eIF6 binding sites. We found a 25% reduction in eIF6 binding sites on the ribosomes of Sbds
, compared to wild type cells (Fig 2H) . Thus, we conclude that SBDS deficiency leads to a late maturation deficit of 60S consistent with the generation of a reduced pool of functional 60S subunits. It is worth to note that 60S peak increases at least 2-fold (Fig 2A and 2B) , whereas eIF6 binding sites drop only 25% (Fig 2H) .
We asked the consequences of the maturation deficit on translation. We developed a fully reconstituted in vitro model, in which translation competent extracts are prepared from equal amount of cells, normalized to the number of ribosomes and transduced with defined amounts of exogenous mRNA. This experiment allows to measure the maximal translational capability per cell/per ribosome. Ribosomal extracts from Sbds R126T/R126T MEF showed around 70% reduction in the translational capability of a cap-dependent reporter (Fig 3A) . medium to high levels of puromycin. Taken together, our results demonstrate that R126T mutation leads to a strong reduction of the pool of 60S subunits competent for translation.
SBDS deficiency causes limited changes in the translation of specific mRNAs but leads to snoRNAs' accumulation on immature 60S
An obvious question is whether the impaired maturation of 60S ribosomes, associated with a reduced translational capability in Sbds R126T/R126T cells, results in a qualitative difference of translation. We decided to proceed with an RNASeq study on total RNA extracted from sucrose gradient collected fractions. We studied 1) RNAs associated to polysomes, 2) RNAs associated to the 80S and 3) steady-state mRNA levels (total RNA) (Fig 4) . The isolated fractions are shown in Fig 4A and 4B . The combination of these parameters allowed us to define the overall translational and transcriptional status associated with Sbds R126T/R126T mutation, assuming that mRNAs differentially localized to either polysomes or 80S are controlled at the translational level. We have decided to use this strategy over ribosome profiling because a) altered 60S subunits may lead to abnormal RNA protection, b) the big change in the 80S monosomal peak found in Sbds R126T/R126T cells is difficult to be normalized, and c) to efficiently reach deepness of more than 2x10 7 reads. S1 File contains read counts of polysomes and total RNAs. S2 File contains read counts of 80S. By comparing the polysomes of Sbds RESCUE and Sbds
MOCK
, we identified 844 modulated genes (Fig 4C; S1 File) , most of them enriched in presence of mutant SBDS. However, when we estimated the translational efficiency, i.e. bona fide polysomal enrichment, by normalizing each mRNA level on the polysome to the amount present on the total, we found only 74 mRNAs with a significant modulation. Of these 74, 31 had less than 10 normalized read counts average expression, suggesting that fluctuations of poorly expressed mRNAs may contribute to the observed effects. The analysis of translation efficiency of Sbds RESCUE and Sbds MOCK confirmed that they do not differ in qualitative translational regulation ( Fig 4D) . The analysis on RNAs enriched on 80S subunits unveiled 250 genes modulated in 80S Sbds MOCK compared to 80S from Sbds cells (Fig 4E; S2 File) . However, identical to what we observed in the polysomal fraction, also in this case the mRNAs modulation on 80S followed the steady state levels (S3A and S3B Fig) as well the polysomal. Taken together, the data suggest that SBDS loss induces a solid transcriptional rewiring due to a general impairment of translation rather than specific translational regulation.
By analyzing polysomal versus steady state mRNAs and 80S modulated in Sbds mutated cells we made two major observations: a) a 4-fold enrichment of snoRNAs ACA8 and ACA31 . ACA8 and ACA31 drive the pseudouridylation of 28S rRNA U3832 and U3713 on the 60S. Other snoRNAs were not changed ( Fig 4F; S1 and S2 Files). Intriguingly, there was no overlap between the genes regulated at the polysomal level by Sbds mutation (S1 File), to the ones we previously found regulated by eIF6 deficiency [41] .
In conclusion, our data (Figs 2G, 2H, 3 and 4) suggest that the lack of mature 60S leads to a general reduction of translational capability associated with transcriptional rewiring.
The loss of functional SBDS causes an alteration in the transcriptome that indicates reduced synthetic and energetic capability but increased lysosome trafficking and altered proteostasis
The limited specific translational changes seen at the polysomal level (Fig 4) , and the strong reduction in the maximal translational capability (Fig 3) were mirrored by a complex rewiring of gene expression and metabolism of SBDS deficient cells (Fig 5) . Hereafter, we describe the transcriptional and metabolic changes directly due to SBDS deficiency, i.e. fully rescued by SBDS readministration in the Sbds R126T/R126T background. To simplify, 527 genes were at least 2-fold altered at the transcriptional level in Sbds MOCK cells, all of them presenting concomitant changes in the polysomal pool. Functional analysis by classical Gene Ontology (GO) for the Molecular Function Domain was performed on these 527 genes. Twentyseven ontology terms grouped in ten emerging categories were found as significantly enriched. Gene Set Association Analysis (GSAA) on both polysomal and total fractions confirmed the findings of the classical (GO) gene ontology (S3 File). Globally, we found that SBDS mutant cells had a decrease in genes encoding for the ribosomal and respiratory chains, and an increase in the lysosomal capability. We will specifically describe some of them. We found upregulated (both at the polysomes and at the steady-state level) mRNAs with peptidase activity including lysosomal cathepsins such as Ctsb, Ctsd, Ctsk and Ctsl (Fig 5A) , and lysosomal genes with vacuolar ATPase activity, including Atp6ap1, Atp6ap2 and Atpv0b (Fig 5A, S1 File) . Validation was confirmed by quantitative PCR (Fig 5B) . M6pr, Lamp1 and Atp6ap1 upregulation suggests increased lysosomal activity associated with Sbds mutation, whereas increased CtsB suggests higher degradation activity. Consistently, we found in Sbds MOCK cells an increase in cell acidification by the Lysotracker assay ( Fig 5C) and an increase in Lamp1 positive cells by immunofluorescence (Fig 5D and 5E In conclusion, we demonstrate that the reduction of SBDS activity causes a reduction of a global translational capability and a cellular adaptation with less energy production and more compensatory catabolic capability. We focused our attention on information deriving from LINCS/CMap project to evaluate if the gene expression profile found altered in the total fraction of Sbds R126T/R126T MEFs cells was similar to transcriptional changes induced by drugs, observed in other cell types and to eIF6 deficiency [41] . Analysis performed by Query web tool on the complete list of modulated genes, and on a subset of the most changed ones identifies three common PKC activators: ingenol, phorbol-12-myristate-13-acetate and prostratin (S3 File).
Sbds
R126T/R126T cells display a modest drug signature predicting stress sensitivity Overall the analysis on SBDS deficient cells suggests that they have an impaired translational capability that leads to a compensatory transcriptional and metabolic rewiring that favors a catabolic processes and a state of low energy versus high synthetic capability. We reasoned that the transcriptional signature generated by SBDS deficiency could lead to a differential sensitivity to drugs or stressors which may be exploited at a therapeutic level. In principle, inhibitors that preferentially repress the growth of Sbds R126T/R126T immortalized MEFs may be of use in treating SDS patients who are affected by Acute Myeloid Leukemia (AML). On the contrary, selective stimulators of growth could be potentially interesting for early-phase of the disease, for instance in the context of neutropenia or pancreatic insufficiency. We decided to proceed with two different screenings, the first based on 100 compounds selected from commercial oral drugs (S4 File). We evaluated the response signature to drugs associated to R126T mutation by measuring cell viability after 48h of treatment. We found that overall Sbds
R126T/R126T
MEFs were similar to Sbds
MOCK
, and wt to Sbds RESCUE . This said, the signature profile that we found was surprisingly similar between wt and SBDS deficient cells (Fig 6A) , with only one exception. In particular, we found increased sensitivity of Sbds R126T/R126T the AnnexinV/7AAD positive population, and we did not find any differences between the two genotypes ( Fig 7A) . Treatment of cells with UV pulses caused an increase in cell death (Fig 7A) , that was significantly more marked in Sbds R126T/R126T and in Sbds MOCK respect to wild type or Sbds RESCUE cells (Fig 7B) . We analyzed DNA damage by examining cells with the COMET assay (Fig 7C and 7D 
Discussion
Our study suggests a model (Fig 8A) that may explain the pathogenic culprit of SDS and will be first described. The table in Fig 8B outlines the phenotypes that we have observed.
A simple model for SBDS-driven pathological symptoms is based on a threshold concept. Total null SBDS mutations are never observed in humans indicating that a zero threshold of SBDS is incompatible with life. Mutant SBDS has a residual activity. This activity is sufficient for, i.e., normal proliferation, but becomes limiting for efficient colony formation or escaping senescence. If senescence is bypassed by oncogene-driven immortalization and transformation, then, SBDS remains still limiting for survival in nude mice. We can therefore imagine that each individual cell, in each moment, may or may not meet the condition of insufficient SBDS activity, with subsequent effects. Indeed, by the SUnSET protocol we see that only some SBDS mutant cells do not reach high translation levels.
If the threshold is not reached, our study supports a model in which SBDS deficiency leads primarily to a delayed maturation of 60S ribosomal subunits. We confirm that the number of eIF6 binding sites on 60S ribosomes is reduced, consistent with reduced generation of free 60S and with a proposed model of SBDS-mediated eIF6 release in the late maturation of 60S, in cooperation with EFL1 [26] . In detail, we quantify a 25% decrease of eIF6 binding sites on 60S, similar to [42] . We also report that the increase of free 60S is 2-fold, the amount of accumulated ACA8/ACA31 snoRNAs on immature 60S is 4-fold, and ribosomal extracts from SBDS mutants have a 70% reduction in translational capability. Apparently, the ribosomal deficit due to SBDS mutation is more pervasive than expected and suggests the generation of a bulk of immature 60S that are poorly active in translation, even if eIF6 is released. This said, eIF6 release may be critical in the rescue of some mature ribosomes and the alleviation of pathological consequences.
A variety of proxyes due to reduced SBDS activity are evident. Indeed, adaptation is evident in the absence of overt signs of SBDS insufficiency. Even if SBDS mutant cells proliferate normally in rich media, they show a signature with reduced energy level, increased lysosomal capability, decreased ribosomal production and less oxygen consumption. The drug screening identified a subtle signature of fragility which may contribute to the pathology. Previously, it was reported excess protease secretion in SDS-derived iPSC [43] , reduced respiration in yeasts and mammalian cell models [34] , and less ATP [35] that together with our extended gene signature define a status of reduced anabolic capability. This may be a keyfactor for rescuing the phenotype. Stimulators of ATP production, for instance, may have an impact on the disease. Our initial drug screening suggests that efforts in this direction may be valuable: we screened drugs for survival activity and found that SBDS mutants are remarkably similar to wt cells. However, a screening for a closer proxy of SBDS deficiency such as ATP levels, may lead to successful compounds.
We think that increased AML in SDS patients is a defect due to impaired host-cancer interplay, rather than due to genetic instability. If anything, SBDS-deficient cells are very resistant to oncogenic transformation and unable to grow in unfavourable conditions like the ones generated in tumors (see xenografts). In the bone marrow of SDS models, the neutrophil lineage can be impaired by the absence of sufficient endogenous SBDS activity [9] . SDS patients have neutropenia [44] . It is known that severe congenital neutropenia is associated with the progression to acute myeloid leukemia [45] . Therefore, we speculate that neutropenia in the bone marrow niche [30, 42] may lead to expansion of tumor cells that cannot be eliminated by proper immunosurveillance. Similar suggestions came from mouse work [46] . In summary, for therapy, we need to address which cell is directly affected by SBDS deficiency.
A divergence between our studies and previously published works relates to ROS [28] production. In our hands we did not find evidence for increased ROS production. It is possible that impaired ROS balance is observed as an indirect effect driven by mitochondrial alterations in specific cells, but is not a direct proxy of SBDS deficiency.
Finally, we would like to comment on translational control driven by SBDS and eIF6. SBDS insufficiency generates a unique phenotype. Similarly to SBDS mutants, eIF6 depletion protects from oncogene-induced transformation [25, 47] , whereas its amplification is oncogenic [48, 49] . eIF6 depletion does not induce senescence [25] , but induces a different transcriptional rewiring [41] , a divergent bone marrow phenotype affecting platelets [50] , and a generally improved metabolic status [41] . SBDS depletion reduces the translation of mRNAs undergoing reinitiation, as CEBP/β derived LIP peptide [26] . In our study the decrease of CEBP/β mRNA on polysomes driven by SBDS deficiency is around 10% (S1 Table) . eIF6 depletion reduces both reinitiation and LIP expression as well as the translation of G/C rich mRNAs [41] . To summarize, the specific effects of eIF6 loss and SBDS loss are different, but overall they suggest that both eIF6 and SBDS have a stimulatory role in protein synthesis. In yeast and Dictyostelium eIF6 mutants revert the SBDS loss [19, 20, 22] . We speculate that these mutants are gainof-function genes and that eIF6 agonists may be beneficial to the disease.
In conclusion, our results support the idea that cells with reduced SBDS activity are able to grow and cycle as well as wild type cells in proper conditions, but if they drop below a SBDS threshold level they show a phenotype. However, the adaptation signature suggests logical roads for improving their fitness. In the long run a screening for compounds which may accelerate the release of eIF6 from 60S subunits can be helpful to discover specific drugs for treating SDS (assuming that a modest increase in active 60S can strongly ameliorate the phenotype). Alternatively, screening on proxyes such as ATP levels may lead to faster therapeutic options.
Materials and Methods
Cell culture and infections
Primary wild type and Sbds R126T/R126T MEFs (E12.5) were grown in DMEM (Lonza), supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin, streptomycin, L-glutamine, and maintained at 37˚C and 9% CO 2 . Mycoplasma testing was performed before experiments. These cells were infected at early passages through retroviral vectors carrying DNp53 + oncogenic H-ras V12 [25] . After immortalization, cells were maintained at 37˚C and 5% CO 2 . 
Transformation assay, soft agar and in vivo tumor growth
For the transformation analysis, primary fibroblasts were infected at early passage with DNp53 + H-ras V12 retroviral vectors and left to grow at overconfluency. Foci were counted 3 weeks after infection and cells were recovered for in vivo experiments. Eight-weeks old CD1 athymic nude mice were used for detecting tumor growth after a subcutaneous injection of in vitro transformed MEFs (500,000 cells/mouse). Tumor growth was monitored and animals were euthanized when the tumor reached the size of 400 mm3. All experiments involving mice were performed in accordance with Italian National Regulations. Experimental protocols were reviewed by local Institutional Animal Care and Use Committees. The soft agar formation assay and the focus formation assay were performed as described previously [51] . In vitro assays were performed at least three times, each in triplicate.
Polysome profiles
Growing cells were lysed in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 30 mM MgCl 2 , 0.1% Nonidet P-40, 100 μg/ml cycloheximide and 40 U/mL RNasin. After centrifugation at 12,000 r. p.m. for 10 min at 4˚C, cytoplasmic extracts with equal amounts of RNA (10 OD 260 ) were loaded on a 15-50% (or 10-30%) sucrose gradient dissolved in 50 mM NH 4 Cl, 50 mM TrisAcetate, 12 mM MgCl 2 , 1 mM DTT and centrifuged at 4˚C in a SW41Ti Beckman rotor for 3 h 30 min at 39,000 r.p.m. Absorbance at 254 nm was recorded by BioLogic LP software (BioRad) and fractions (1.5 mL each) were collected for subsequent proteins or RNA extraction. Each experiment has been performed at least six times, for each condition.
RNA isolation and RNA sequencing and quantitative PCR
Total RNA was extracted from sucrose gradient aliquots. For the 15-50% gradient, we pulled fractions corresponding to polysomes in one fraction, and we pulled 100 μL from each fraction from the whole gradient in one fraction (total). For the 10-30% gradient, we pulled fractions corresponding only to the 80S peak in one fraction, named 80S, and we used as total RNA aliquots from the pre-gradient loading extract (pre-load). Afterward, we added to samples proteinase K (to a final concentration 100μg/mL) and SDS (to a final concentration of 1%) and we incubated them for 1 h at 37˚C. Total RNA was then extracted by phenol/chloroform/isoamyilic acid method (https://tools.thermofisher.com/content/sfs/manuals/trizol_reagent.pdf).
Libraries for Illumina sequencing were constructed from 100 ng of total RNA with the Illumina TruSeq RNA Sample Preparation Kit. The generated libraries were loaded on to the cBot (Illumina) for clustering on a HiSeq Flow Cell v3. The flow cell was then sequenced using a HiScanSQ (Illumina). A paired-end (2×101) run was performed using the SBS Kit v3 (Illumina). Experiments were performed in biological triplicates. For quantitative PCR, 150 ng of RNA was retrotranscribed according to SuperScriptTM III First-Strand Synthesis SuperMix manufacturer protocol (18080400, Life Technologies). For RNASeq validation, Taqman probes specific for Atp6ap1 (Mm01187488_g1), Lamp1 (Mm00495262_m1), Ctsb (Mm01310506_m1) and M6pr (Mm04208409_gH) were used. Target mRNA quantification was performed by using ΔCt-method with 18S rRNA as an internal standard, performed on a StepOne Puls System (Applied Biosystems). Results are represented as means + s.d. of three independent experiments.
Bioinformatics analysis
Read pre-processing and mapping. Three biological replicates were analyzed for polysomal, total and 80S fractions, with the exception of 80S Sbds RESCUE condition, for which two biological replicates were available. Three replicates were examined for pre-load samples. Raw reads were checked for quality by FastQC software (version 0.11.2) (Available from: http:// www.bioinformatics.babraham.ac.uk/projects/fastqc), and filtered to remove low quality calls by Trimmomatic (version 0.32) [52] using default parameters and specifying a minimum length of 50. Processed reads were then aligned to mouse genome assembly GRCm38 (Ensembl version 77) with STAR software (version 2.3.0e) [53] . Gene expression quantification and differential expression analysis. HTSeq-count algorithm (version 0.6.1, options = no, gene annotation release 77 from Ensembl) [54] was employed to produce read counts for each sample. To estimate differential expression, the matrix of read counts produced by HTSeq was analyzed by DESeq2 (version DESeq2_1.6.3) [55] . In a first step, differential expression analysis by DeSeq2 algorithm was performed to compare Sbds MOCK versus Sbds RESCUE genotypes in polysomal or in total fractions (12 samples overall). Read counts were normalized by calculating a size factor, as implemented in DESeq2.
Independent filtering procedure was then applied, setting the threshold to the 65 percentile; 14471 genes were therefore tested for differential expression. Significantly modulated genes in polysomal or total fractions were selected by considering an absolute value of log2 fold change higher than 1 and a false discovery rate lower than 5%. In the same analysis framework, the moderate fold-change (as implemented by in the 80S fraction (5 samples). Independent filtering threshold of 65% resulted in the selection of 14484 genes for statistical testing. In order to compare the levels of 80S and pre-load, DESeq2 normalization and regularized log transformation steps were performed on the samples belonging to these experimental conditions together, and the genes of interest were visualized by a heat map. Analyses were performed in R version 3. 
Gene set association analysis
Gene set association analysis for polysomal and total fractions was performed by GSAA software (version 1.2) [57] . Raw reads for about~22000 genes identified by Entrez Gene ID were analyzed by GSAASeqSP, using gene set C5 (mouse version retrieved from http://bioinf.wehi. edu.au/software/MSigDB) and specifying as permutation type 'gene set' and as gene set size filtering min 15 and max 800.
CMap analysis
Analysis on CMap/LINCS gene signatures was performed using the 'Query' web tool (http:// apps.lincscloud.org/query), that, taking as input a list of genes, computes the connectivity between this set and the gene expression signatures of the LINCS database. Human orthologs of mouse genes were retrieved relying on Biomart web tool (http://www.ensembl.org/ biomart); only genes with a one-to-one orthologs relationship were maintained for downstream computations. Query tool was first applied on the list of 726 mouse genes significantly modulated in the total fraction; chemical compounds showing a mean rank value of at least 90 on 6 cell lines were selected as interesting. As second strategy, the same procedure was applied on the genes showing a robust modulation (143 genes with a fold-change higher than 3 as absolute value) and then selecting chemical compounds with a mean rank value of at least 90 on 4 cell lines. To find perturbations that are consistently retrieved, the overlap between the two analyses was considered as final result.
Western blotting and antibodies
SDS-PAGEs were performed on protein extracts obtained with RIPA buffer (10 mM Tris-HCl, pH 7.4, 1% sodium deoxycholate, 1% TritonX-100, 0.1% SDS, 150 mM NaCl and 1 mM EDTA, pH 8.0). Protein concentration was determined with BCA analysis (Thermo Fisher Scientific). Equal amounts of proteins were loaded on each lane and separated on a 10% SDS-PAGE, then transferred on a PVDF membrane. The membranes were blocked in 10% Bovine Serum Albumin (BSA) in Phosphate Buffer Saline (Na 2 HPO 4 10 mM, KH 2 PO 4 1.8 mM, NaCl 137 mM, KCl 2.7 mM, pH 7.4) (PBS) with Tween (0,01%) for 30 minutes at 37˚C. The following primary antibodies were used: β-actin (CST 4967L 1:4000), SBDS (Santa Cruz S15 SC49257 1:500) H-RAS (Santa Cruz SC520, 1:1000), Lamp1 (Santa Cruz SC20011, 1:200), AMPK (CST 5831 1:1000), phospho-AMPK (CST 2535 1:1000), phospho-AMPK Substrates (CST 5759, 1:1000). The following secondary antibodies were used: donkey anti-goat IgG HRP (Santa Cruz SC2020, 1:2000), donkey anti-rabbit IgG HRP (Amersham NA934 1:5000) and donkey anti-mouse IgG HRP (Santa Cruz, SC2005 1:5000). Each experiment was performed at least three times, each time in triplicate.
Immunofluorescences and antibodies
Cells were seeded the day before the staining. The next day, cells were rinsed three times with PBS then fixed with ice cold methanol 100% for 10 minutes at -20˚C. After three washes with PBS, cells were blocked in Normal Goat Serum 5%, for 1 hour at room temperature. Primary antibodies were incubated overnight at 4˚C, and after three washes with PBS, secondary antibodies were incubated 3h at room temperature in the dark. After three washes with PBS, cells were incubated with DAPI (Molecular Probes NucBlue Live ReadyProbes Reagent R37605) as manufacturer protocol, then washed and mounted on slides with Mowiol 20%. All the antibodies were diluted in blocking solution. The following primary antibodies were used: NPM [25] , SBDS (Santa Cruz S15 SC49257 1:25), eIF6 [58] (1:100), Lamp1 (Santa Cruz sc-20011 1:100). The following secondary antibodies were used: donkey anti-goat, donkey anti-mouse, donkey anti-rabbit (Alexa Fluor secondary antibodies, Molecular Probes 1:500). The cells were examined by confocal microscopy (Leica SP5) and analyzed with Volocity 6.3 software (Perkin Elmer). Immunofluorescence experiments were performed at least three times, in triplicate.
Comet assay
Comet assay was performed following the manufacturer protocol (Trevigen, 4250-050-K). The stained nuclei were then examined by confocal microscopy (Leica SP-5), and analyzed (n!30 for each condition) with Comet Assay IV software (Perceptive Instruments). The experiment was performed three times in triplicate. 
Ribosome biogenesis
In vitro translation assay
For in vitro translation assays, we used cell extracts prepared as described [59] with some optimizations. 80% confluent cells were trypsinized and lysed for 45 minutes at 4˚C in 10 mM HEPES pH 7.6, 10 mM potassium acetate, 0.5 mM magnesium acetate, 5 mM DTT and protease inhibitor (Promega). Lysates were homogenized by syringing through a 27G, 3/ 4-inch needle. Lysates were clarified by centrifugation at 18.000 g for 1 minute and protein concentration was determined by BCA quantification assay. To make translation fully dependent on exogenously added mRNA, lysates were treated with 15 U/ml Micrococcal nuclease (MN Boehringer) and 0.75 mM CaCl 2 and incubated at 25˚C for 7 minutes. EGTA was added to terminate the reaction.
For the translation assay, 6 μl of cell extract were mixed to 1.2 μl of Master Mix (125 mM HEPES, 10 mM ATP, 2 mM GTP, 200 mM creatine phosphate, 0.2 mM aminoacid mix without methionine (Promega), 0.25 mM spermidine, 20 mM of L-methionine, 50 mM potassium acetate, 2.5 mM magnesium acetate, 20 U of RNAsin (from Promega) and 0.5 μg of purified reporter-encoding mRNA). The mRNA was obtained by using the Megascript T7 kit (Ambion) to perform the in vitro transcription reaction supplemented with 2 mM cap analog [M7G(5')PPP(5')G] (Ambion). The mix for the in vitro translation reaction was then incubated for 90 minutes at 30˚C. Dual-Glo Luciferase Assay kit (Promega) was used to read Firefly and Renilla luciferase output with GloMax Luminometer (Promega). In vitro translation experiments were performed at least three times, in triplicate.
SUnSET assay
For protein synthesis measurements, we adapted SUnSET protocol [60] . 70% confluent cells were treated with 5μg/ml puromycin for 10 minutes, then trypsinized and centrifugated 5 minutes at 500 g. Then, cell were fixed and permeabilized using reagents from the Foxp3/Transcription Factor Staining Buffer Set (Affymetrix, 5523-00), incubated with anti-puromycin 12D10 (1:2000, Millipore, MABE343) and finally with secondary antibody Alexa Fluor 488 Goat anti-Mouse (Invitrogen) and DAPI, according to manufacturer protocol. Cells were then analyzed with FACSCanto II (BD Bioscience) and analyzed with FlowJo8.8.7 software. SUn-SET experiments were performed at least three times, in triplicate.
Drug screenings
100 molecules screening. Cells were plated in 96 well (6000 cells/well) 4 hours before drug treatments. The list of all drugs with their relative concentration is in the S4 File. Unless specified, the drug treatment time is 48 hours. Cell viability was measured with Cell Titer Blue (Promega, G8080), according to the manufacturer's protocol. All treatments were performed at least three times, in triplicate.
FDA screening
1280 approved drugs were analyzed for their impact on Sbds R126T/R126T cells growth. Cells were seeded using a Multidrop Combi (Thermo Scientific) in 384 well plates (Perkin Elmer Cell Carrier, collagen coated) at a density of 4000 cells/well. After 24 hours the drugs were supplemented using a Hamilton Starlet liquid handler at a final concentration of 10 μM and cells were treated for 30 hours. The reference compound for toxicity was 5 μM Trichostatin A. Cytotoxicity was than evaluated by measuring in vivo nuclear shrinkage and loss of cells using Hoechst33342, and cell membrane disruption using the cell-impermeant nuclear dye BOBO-3. Briefly, following incubation with the drugs diluted in 50 μl growth medium, 25 μl of a dye cocktail containing 3 μM Hoechst33342 and 2.25 μM BOBO-3 were added and incubation was continued for further 45 min at 37˚C, 5% CO 2 . Images were then immediately acquired and analyzed using the Operetta microscope (Perkin Elmer). For the validation of hits, 6-point dose-responses for each compound in duplicate were used (ranging from 30uM to 0.12uM). The number of dead cells/total number of cells was the readout of the assay, where dead cells correspond to nuclei stained with BOBO-3 and the total number of cells correspond to the nuclei stained with Hoechst33342.
Metabolism analysis
Secreted lactate. Cells were plated in 6 well dishes in high-glucose medium for 24 hr and then switched to serum-free high-glucose (4,5 g/L) for 4 hr as indicated in [61] . Lactate secreted into the medium was measured using a fluorogenic assay, Lactate Assay Kit (Biovision). Average of fluorescence intensity was calculated for each condition replicates. Values were normalized to protein content obtained from the same wells.
ATP levels. For ATP measurements, samples were homogenized in ice-cold ATP buffer (20 mM Tris, pH 7.5, 0.5% Nonidet P-40, 25 mM NaCl, 2.5 mM EDTA) for 5 min. Lysates were centrifuged at 13,000 g for 30 min. Proteins were quantified by BCA analysis. Luminometric determination of ATP was assayed using the ATP-determination kit (Molecular Probes) according to [62] .
Glycolysis and extracellular O 2 consumption assays. For respiration and glycolysis analysis, fluorogenic kits were used (respectively, Abcam ab197243 and ab197244), following manufacturer protocols. Average of fluorescence intensity was calculated for each replicate, and then values were normalized for cells number.
Pyruvate levels. For pyruvate analysis, a fluorimetric kit was used (BioVision, K609-100) following manufacturer protocol. Average of fluorescence intensity was calculated for each replicate, and then values were normalized for protein content obtained. All assays were performed at least three times, in triplicates.
Cell death and ROS production measurement
All analysis were performed using the FACSCanto II Flow cytometer (BD) and analyzed with FlowJo software (BD). All experiments were performed when cells reached the confluence of 70%. For the apoptosis analysis, cells were UV irradiated with a cross-linker (9999 μJ/cm2, three times) and cell death was detected by using the 7AAD-Annexin V kit (640926, BioLegend). For ROS measurement, cells were incubated with 50 μM H2DCF-DA (2', 7', -dichlorodihydrofluorescein diacetate, AbCam Ab113851) for 30 min at 37˚C and 5% CO2 and immediately analyzed by flow citometry. All experiments were performed at least three times, in triplicate.
In vitro ribosome interaction assay (iRIA)
iRIA assay was performed as described in [40] . Briefly, 96-well plates were coated with a cellular extract diluted in 50 μL of PBS, 0,01% Tween-20, O/N at 4˚C in humid chamber. Coating solution was removed and aspecific sites were blocked with 10% BSA, dissolved in PBS, 0,01% Tween-20 for 30 minutes at 37˚C. Plates were washed with 100 μl /well with PBS-Tween. 0,5 μg of recombinant biotynilated eIF6 was resuspended in a reaction mix: 2,5 ;mM MgCl 2 , 2% DMSO and PBS-0.01% Tween, to reach 50 ;μl of final volume/well, added to the well and incubated with coated ribosomes for 1 hour at room temperature. To remove unbound proteins, each well was washed 3 times with PBS, 0,01% Tween-20. HRP-conjugated streptavidine was diluted 1:7000 in PBS, 0,01% Tween-20 and incubated in the well, 30 minutes at room temperature, in a final volume of 50 μl. Excess of streptavidine was removed through three washes with PBS-Tween. OPD (o-phenylenediamine dihydrochloride) was used according to the manufacturer's protocol (Sigma-Aldrich) as a soluble substrate for the detection of streptavidine peroxidase activity. The signal was detected after the incubation, plates were read at 450 nm on a multiwell plate reader (Microplate Bio-Rad model 680). This experiment was performed at least three times, in triplicate.
Lysotracker assay
Cells were seeded the day before the assay. The next day, cells were incubated with Lysotracker DeepRed (Thermo Fisher Scientific L12492) according to the manufacturer protocol. The cells were examined with Nikon Ti-Eclipse microscope and analyzed with Volocity 6.3 software (Perkin Elmer). For subsequent analysis, cells were then fixed with paraformaldehyde 3% for 10 minutes at room temperature and nuclei were stained with DAPI (Molecular Probes NucBlue Live ReadyProbes Reagent R37605) as manufacturer protocol, then washed and mounted on slides with Mowiol 20%. The cells were examined by confocal microscopy (Leica SP5) and analyzed with Volocity 6.3 software (Perkin Elmer). Lysotracker experiments were performed at least three times, in triplicate.
Accession number
The RNA seq data are available at www.ebi.ac.uk/arrayexpress with accession number ID: E-MTAB-5089. 
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